|
Becton Dickinson
anti-cd45-bv785 Anti Cd45 Bv785, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/cd45+bv785/anti+cd3/pmc05542404-210-24-27 Average 90 stars, based on 1 article reviews
anti-cd45-bv785 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Elabscience Biotechnology
cd45 bv785 ![]() Cd45 Bv785, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/cd45+bv785/PE+Anti-Mouse+CD45+Antibody/pmc12876979-90-19-21 Average 94 stars, based on 1 article reviews
cd45 bv785 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
cd45 bv785 ![]() Cd45 Bv785, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/cd45+bv785/Cas9+(S%2E+aureus)+Mouse+mAb/pmc09827473-15-0-2 Average 93 stars, based on 1 article reviews
cd45 bv785 - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Sony
cd45-bv785 (clone hi30) ![]() Cd45 Bv785 (Clone Hi30), supplied by Sony, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/cd45+bv785/bv570+anti+cd45/pmc07051942-24-79-82 Average 90 stars, based on 1 article reviews
cd45-bv785 (clone hi30) - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Brilliant Violet 785 anti-mouse CD45 [30-F11]; Isotype: Rat IgG2b, κ; Reactivity: Mouse; Apps: FC; Size: 50 μg
|
Buy from Supplier |
|
Brilliant Violet 785 anti-mouse CD45.2 [104]; Isotype: Mouse (SJL) IgG2a, κ; Reactivity: Mouse; Apps: FC; Size: 50 μg
|
Buy from Supplier |
|
Brilliant Violet 785 anti-human CD45 [HI30]; Isotype: Mouse IgG1, κ; Reactivity: Human, Cross-Reactivity: Chimpanzee; Apps: FC; Size: 25 tests
|
Buy from Supplier |
|
Brilliant Violet 785 anti-mouse CD45.1 [A20]; Isotype: Mouse (A.SW) IgG2a, κ; Reactivity: Mouse; Apps: FC; Size: 50 μg
|
Buy from Supplier |
|
Brilliant Violet 785 anti-human CD45RA [HI100]; Isotype: Mouse IgG2b, κ; Reactivity: Human, Cross-Reactivity: Chimpanzee; Apps: FC; Size: 25 tests
|
Buy from Supplier |
|
Brilliant Violet 785 anti-human CD45RO [UCHL1]; Isotype: Mouse IgG2a, κ; Reactivity: Human, Cross-Reactivity: Chimpanzee, Common Marmoset; Apps: FC; Size: 25 tests
|
Buy from Supplier |
|
Brilliant Violet 785 anti-mouse/human CD45R/B220 [RA3-6B2]; Isotype: Rat IgG2a, κ; Reactivity: Mouse, Human, Cross-Reactivity: Cat (Feline); Apps: FC; Size: 125 μl
|
Buy from Supplier |
Image Search Results
Journal: Cell Death & Disease
Article Title: Targeting ENO1 reprograms macrophage polarization to trigger antitumor immunity and improves the therapeutic effect of radiotherapy
doi: 10.1038/s41419-026-08416-7
Figure Lengend Snippet: A A total of 2.5 × 10 5 CT26 cells were subcutaneously injected into the left legs of BALB/c mice for 4 days and then intraperitoneally administered anti-ENO1 antibodies (HuL001, 20 mg/kg) five times at three-day intervals. Local radiotherapy was given on Day 10. The tumor volume was recorded every three days. * p < 0.05 and ** p < 0.01. Two-Way ANOVA test ( n = 4). B The resected tumors were weighed on Day 30. * p < 0.05 and *** p < 0.001. One-Way ANOVA test ( n = 3). C The densities of M1 (CD80 + ) and M2 (CD206 + ) macrophages in resected tumors were analyzed by immunofluorescence staining. D The quantification of M1 (CD80 + ) and M2 (CD206 + ) macrophages in resected tumors. * p < 0.05 and ** p < 0.01. One-Way ANOVA test ( n = 3). E The mRNA levels of Cd86 and Cd163 in resected tumors were analyzed by qRT‒PCR ( n = 3). * p < 0.05, ** p < 0.01 and *** p < 0.001. One-Way ANOVA test ( n = 3). F The frequencies of M1 (CD11c + CD11b + F4/80 + CD45 + 7AAD - CD3 - CD19 - ) and M2 (CD206 + CD11b + F4/80 + CD45 + 7AAD - CD3 - CD19 - ) tumor-infiltrating macrophages were analyzed by flow cytometry ( n = 3-4). * p < 0.05 and *** p < 0.001. One-Way ANOVA test. G The quantification of the M1/M2 ratio is shown ( n = 3). * p < 0.05 and ** p < 0.01. One-Way ANOVA test ( n = 3). H The frequencies of CD4 (CD4 + CD3 + CD45 + 7AAD - ) and CD8 (CD8 + CD3 + CD45 + 7AAD - ) tumor-infiltrating T cells were analyzed by flow cytometry ( n = 3-4). * p < 0.05. One-Way ANOVA test. I The quantification of CD8 + TILs is shown. * p < 0.05. One-Way ANOVA test ( n = 3). J The frequency of regulatory CD4 T cells (CD25 + CD127 - CD4 + CD3 + CD45 + 7AAD - ) was analyzed by flow cytometry ( n = 3-4). K The quantification of the CD8/Treg ratio is shown. * p < 0.05 and ** p < 0.01. One-Way ANOVA test ( n = 3). L The densities of dendritic cells (CD11c + ) and cytotoxic T cells (CD8 + ) in resected tumors were analyzed by immunofluorescence staining. The density of CD11c + DCs is shown. * p < 0.05 and ** p < 0.01. One-Way ANOVA test ( n = 3). M The density of CD8 + TILs is shown. * p < 0.05 and ** p < 0.01. One-Way ANOVA test ( n = 3).
Article Snippet: The cells were stained with different antibodies against combinations of surface markers: (1) CD4 and CD8 T cells: ViaDyeRed,
Techniques: Injection, Immunofluorescence, Staining, Flow Cytometry
Journal: Cell Death & Disease
Article Title: Targeting ENO1 reprograms macrophage polarization to trigger antitumor immunity and improves the therapeutic effect of radiotherapy
doi: 10.1038/s41419-026-08416-7
Figure Lengend Snippet: A A total of 5 × 10 5 CT26 cells were subcutaneously injected into the left legs of BALB/c mice for 5 days and then intraperitoneally administered with anti-ENO1 antibodies (HuL001, 40 mg/kg) or clodronate liposomes (50 μL/mouse) on the indicated days ( n = 5). Local radiotherapy was given on Day 10. The tumor volume was recorded every three days. * p < 0.05. Two-Way ANOVA test ( n = 4). B The densities of M1 (CD80 + ) and M2 (CD206 + ) macrophages in resected tumors were analyzed by immunofluorescence staining. The quantification of M1 (CD80 + ) and M2 (CD206 + ) macrophages in resected tumors. * p < 0.05 and *** p < 0.001. One-Way ANOVA test ( n = 3). C 4T1 cells (5 ×10 4 ) were subcutaneously injected into the left legs of BALB/c mice for 4 days and then intraperitoneally administered anti-ENO1 antibodies (HuL001, 20 mg/kg) six times on the indicated days ( n = 5). Local radiotherapy was given on Days 10 and 12. The tumor volume was recorded every three days. * p < 0.05 and *** p < 0.001. Two-Way ANOVA test ( n = 4). D The resected tumors were weighed on Day 40. * p < 0.05. One-Way ANOVA test ( n = 4). E The densities of M1 (CD80 + ) and M2 (CD206 + ) macrophages in resected tumors were analyzed by immunofluorescence staining. F The quantification of M1 (CD80 + ) and M2 (CD206 + ) macrophages in resected tumors. * p < 0.05. One-Way ANOVA test ( n = 3). G The frequencies of M1 (CD11c + CD11b + F4/80 + CD45 + 7AAD - CD3 - CD19 - ) and M2 (CD1206 + CD11b + F4/80 + CD45 + 7AAD - CD3 - CD19 - ) tumor-infiltrating macrophages were analyzed by flow cytometry. * p < 0.05. One-Way ANOVA test ( n = 3-4). H The quantification of the M1/M2 ratio is shown. * p < 0.05. One-Way ANOVA test ( n = 3). I A representative image of flow cytometric analysis of GzmB + (GzmB hi CD8 + CD3 + CD45 + 7AAD - ) T cells. J The frequency of GzmB + (GzmB hi CD8 + CD3 + CD45 + 7AAD - ) T cells was analyzed by flow cytometry. * p < 0.05. One-Way ANOVA test ( n = 3-4). K The density of GzmB + (GzmB hi CD8 + CD3 + CD45 + 7AAD - ) T cells is shown. * p < 0.05. One-Way ANOVA test ( n = 3-4). L The density of IFNγ + (IFNγ hi CD8 + CD3 + CD45 + 7AAD - ) T cells is shown ( n = 3-4). * p < 0.05 and ** p < 0.01. One-Way ANOVA test ( n = 3-4). M The proposed mechanism of TGFβ1/TGFβR/Smad3/PRMT5-mediated ENO1 translocation for lactate release via MCT4.
Article Snippet: The cells were stained with different antibodies against combinations of surface markers: (1) CD4 and CD8 T cells: ViaDyeRed,
Techniques: Injection, Liposomes, Immunofluorescence, Staining, Flow Cytometry, Translocation Assay